肝细胞癌药物市场规模、份额和成长分析（按类型、药物类别、最终用户和地区划分）—产业预测（2026-2033 年）

全球肝细胞癌治疗市场规模预计在 2024 年达到 15.2 亿美元，从 2025 年的 16.4 亿美元增长到 2033 年的 31.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.3%。

由于患者族群结构的变化、政府对癌症治疗领域投入的增加以及标靶治疗研发的进步，全球肝细胞癌（HCC）治疗市场正经历强劲成长。政府对医疗创新的日益重视推动了新治疗方法的推出，包括针对肝癌的精准医疗，而肝癌领域目前仍处于欠发达状态。早期诊断技术的改进以及免疫疗法和联合治疗在医疗系统中的广泛应用进一步促进了这一增长。精准肿瘤学的关键创新，包括基于生物标记的方法和新一代蛋白酪氨酸激酶抑制剂（TKI），正在改变HCC的治疗方式。此外，基于人工智慧的药物发现平台的出现也促进了新型HCC免疫疗法的快速开发和评估。

推动全球肝细胞癌药物市场发展的因素

全球肝细胞癌药物市场主要受疾病盛行率上升的驱动，而疾病盛行率上升的主要原因是抗药性慢性感染疾病（如B型和C型肝炎）的增加。酒精消费量量的增加，以及非酒精性脂肪肝和非酒精性脂肪性肝炎患者人数的增加（肥胖和糖尿病的日益流行加剧了这个健康问题），进一步加剧了这个问题。患者数量的增长以及对有效治疗方法的需求，使得现有疗法和创新治疗方法都面临着强劲的需求。

限制全球肝细胞癌药物市场的因素

全球肝细胞癌治疗市场面临许多挑战，主要原因是免疫疗法和标靶治疗的高昂费用，阻碍了患者获得治疗的机会，尤其是在中低收入地区。此外，成熟市场已实施卫生技术评估（HTA）政策，这可能会延长昂贵疗法的报销流程。这不仅限制了患者的治疗机会，也阻碍了创新治疗方法的及时推广，即使其临床疗效已得到证实。因此，这些因素构成了一种限制市场环境，减少了肝细胞癌治疗领域整体发展的机会。

肝细胞癌药物市场的全球趋势

全球肝细胞癌治疗市场正呈现一个显着趋势：利用PD-1/PD-L1抑制剂、蛋白酪氨酸激酶抑制剂（TKI）和抗血管新生药物的协同作用，而联合治疗正快速发展。整合了Lenvatinib和Bevacizumab等药物的创新联合治疗正在推动临床疗效的改善，死亡风险的显着降低便是明证。 FDA和EMA等监管机构加快核准，进一步促进了这些治疗方法的应用，加速了这一趋势。因此，这个快速成长的市场有望重塑肝细胞癌的治疗模式，并推动患者预后和疾病管理的改善。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 一手和二手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 用例

全球肝细胞癌药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• PD-1/PD-L1抑制剂
• 蛋白酪氨酸激酶抑制剂

全球肝细胞癌药物市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 标靶治疗
• 免疫疗法
• 其他的

全球肝细胞癌药物市场规模（按治疗类型和复合年增长率划分）（2026-2033 年）

• 药物治疗
• 外科手术
• 放射治疗
• 化疗
• 其他的

全球肝细胞癌药物市场依给药途径及复合年增长率划分（2026-2033 年）

• 口服
• 注射
• 其他的

全球肝细胞癌药物市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 居家医疗
• 专科诊所
• 其他的

全球肝细胞癌药物市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 医院药房
• 网路药房
• 零售药房

全球肝细胞癌药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • GCC
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

  主要企业简介

  • Exelixis公司（美国）
  • 默克公司（美国）
  • 阿斯特捷利康（英国）
  • 百时美施贵宝公司（美国）
  • 礼来公司（美国）
  • 新罗仁株式会社（韩国）
  • 拜耳股份公司（德国）
  • 强生全球服务有限公司（美国）
  • 辉瑞公司（美国）
  • F. Hoffmann-La Roche Ltd（瑞士）
  • 吉利德科学公司（美国）
  • 葛兰素史克有限公司（英国）
  • 武田药品工业株式会社（日本）
  • 安进公司（美国）
  • 北极星集团（美国）
  • Hepion Pharmaceuticals, Inc.（美国）
  • Provectus Biopharmaceuticals, Inc.（美国）

结论与建议

Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.11 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The global market for hepatocellular carcinoma (HCC) drugs is experiencing robust growth driven by evolving patient demographics, increased government investments in oncology, and advancements in targeted therapy research and development. Heightened governmental focus on health innovation supports the adoption of new treatments, including precision medicine tailored to liver cancer, which remains an emerging field. The growth is further propelled by improvements in early diagnosis and the rising application of immunotherapies and combination therapies within healthcare systems. Significant innovations in precision oncology are transforming HCC treatment, highlighted by biomarker-guided approaches and next-generation tyrosine kinase inhibitors (TKIs). Additionally, the emergence of artificial intelligence-driven drug discovery platforms is enhancing the rapid development and evaluation of novel immunotherapies for HCC.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatocellular Carcinoma Drugs Market Segments Analysis

Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatocellular Carcinoma Drugs Market

The global market for drugs targeting hepatocellular carcinoma (HCC) is significantly driven by the increasing prevalence of the disease, largely due to the rise of drug-resistant chronic infections such as hepatitis B and C. The upward trend in alcohol consumption, along with a growing number of individuals suffering from nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, exacerbated by rising obesity and diabetes rates, further contributes to this growing health concern. As the patient population expands and the need for effective treatment options intensifies, there is a robust demand for both established therapies and innovative new solutions as they emerge.

Restraints in the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma Drugs market faces significant challenges primarily due to the high costs associated with immunotherapies and targeted therapies, which hinder patient access, particularly in low- and middle-income regions. Additionally, established markets implement health technology assessment policies that can prolong the reimbursement process for expensive treatments. This not only limits patient access but also impedes the timely introduction of innovative therapies, even when their clinical effectiveness has been demonstrated. Consequently, these factors contribute to a constrained market environment, reducing overall opportunities for advancement in the treatment of hepatocellular carcinoma.

Market Trends of the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma (HCC) drugs market is witnessing a notable trend with the rapid expansion of combination therapies that leverage the synergistic effects of PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. These innovative combinations, such as those integrating agents like lenvatinib and bevacizumab, are driving improved clinical outcomes, exemplified by significant reductions in mortality risk. This trend is further fueled by expedited regulatory approvals from agencies like the FDA and EMA, enhancing the adoption of these therapies. Consequently, this burgeoning landscape is set to reshape treatment paradigms for HCC, promoting better patient prognosis and disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors

Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Medication, Surgery
• Radiotherapy
• Chemotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provectus Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations